Shanghai, China – 09 Sep 2026 – Shanghai Bona Biomedical Co., Ltd. (private) has been proposed for inclusion in China’s “Care Program – Extension” rare disease drug incentive pilot, after the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) published a public notice listing the company’s CD19‑targeted gene‑modified allogeneic chimeric antigen receptor T‑cell (CAR‑T) injection for development in relapsed/refractory systemic sclerosis (SSc). The consultation window remains open through 16 September 2026.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Center for Drug Evaluation (CDE), NMPA (China) |
| Action Type | Public notice of proposed inclusion in the Rare Disease Innovative Drug R&D Incentive Pilot (“Care Program – Extension”) |
| Product | CD19‑targeted gene‑modified allogeneic CAR‑T injection |
| Applicant | Shanghai Bona Biomedical Co., Ltd. |
| Planned Indication | Relapsed/refractory systemic sclerosis (SSc) |
| Notice Date | 9 September 2026 |
| Comment Deadline | 16 September 2026 (objections via zhaona@cde.org.cn) |
| Next Steps | Formal pilot inclusion after the notice period; subsequent review under pilot incentives – detailed timelines Not disclosed |
Drug Profile & Mechanism of Action
- Modality: Allogeneic (“off‑the‑shelf”) CAR‑T cell therapy – manufactured from healthy donor T cells rather than harvested from each patient, in contrast to autologous CAR‑T products currently on the market.
- Target: CD19, a surface antigen expressed across the B‑cell lineage; depleting autoreactive B cells has emerged as a mechanistic strategy in B‑cell–driven autoimmune diseases, including systemic sclerosis.
- Innovation: A gene‑modified allogeneic design intended to bypass the manufacturing lead time and patient T‑cell quality constraints of autologous therapy while enabling scalable, repeatable supply.
- Clinical Stage / Data: Not disclosed in the CDE announcement.
Policy Context – “Care Program – Extension” Pilot
- Program: Established under the CDE’s application guidelines for encouraging innovative drug R&D in rare diseases, the pilot is designed to channel regulatory support and review incentives toward candidates addressing conditions of high unmet need.
- Unmet Need: Systemic sclerosis is a rare, progressive autoimmune fibrotic disorder; patients with relapsed/refractory disease have limited therapeutic options, making SSc a priority target for innovative modalities.
- Mechanistic Rationale: CD19‑directed B‑cell depletion represents a departure from conventional immunosuppression, aiming at deep immune reset rather than symptom control – a hypothesis now moving into formally incentivized development in China.
- Incentive Details: Specific benefits conferred by pilot inclusion – Not disclosed in this notice.
Market Impact & Outlook
- China Cell Therapy Landscape: Should the program advance, an allogeneic CAR‑T for autoimmune disease would address key accessibility bottlenecks of autologous products – vein‑to‑vein time, manufacturing failures, and capacity limits – in the world’s second‑largant pharmaceutical market.
- Rare Disease Strategy: The notice reinforces the CDE’s continued push to build a dedicated incentive pathway for rare disease innovation, signaling earlier regulatory engagement for qualifying programs.
- Competitive Edge: Bona’s off‑the‑shelf CD19 approach positions the company in the fast‑expanding autoimmune CAR‑T race, where most competitors remain focused on autologous formats or hematologic oncology.
- Pipeline Positioning: Proposed inclusion elevates the visibility of Shanghai Bona Biomedical’s allogeneic cell therapy platform ahead of formal pilot confirmation; commercialization plans and partnerships – Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the proposed pilot inclusion, regulatory timelines, clinical development, and commercial expectations for Bona Biomedical’s CD19‑targeted allogeneic CAR‑T injection. The proposal remains subject to the public consultation period and final CDE determination; actual results may differ due to regulatory, clinical, manufacturing, and competitive risks.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/f56f5a13f9edb44cbcb4226e2a496efd